TCGA-63-7023-01A-11R-1949-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.710
- E2F_TARGETS+0.620
- MYC_TARGETS_V1+0.590
- G2M_CHECKPOINT+0.570
- OXIDATIVE_PHOSPHORYLATION+0.320
- UNFOLDED_PROTEIN_RESPONSE+0.310
- DNA_REPAIR+0.300
- MTORC1_SIGNALING+0.300
- MITOTIC_SPINDLE+0.280
- SPERMATOGENESIS+0.260
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.470
- COAGULATION-0.420
- IL6_JAK_STAT3_SIGNALING-0.400
- ANGIOGENESIS-0.390
- INFLAMMATORY_RESPONSE-0.370
- COMPLEMENT-0.360
- TGF_BETA_SIGNALING-0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.350
- KRAS_SIGNALING_UP-0.340
- TNFA_SIGNALING_VIA_NFKB-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-34-5231-01A-21R-1820-07 | — | cohortSQ2 | 0.943 |
| 2 | TCGA-60-2711-01A-01R-0851-07 | — | cohortSQ2 | 0.910 |
| 3 | TCGA-38-4630-01A-01R-1206-07 | — | cohortMD1 | 0.901 |
| 4 | BS_RD4D5F9F | medulloblastoma | — | 0.900 |
| 5 | AUR-AG0N-TTM1-A-1-1-R-A743-41 | — | E | 0.899 |
| 6 | SRR15030859 | — | — | 0.899 |
| 7 | MNG531 | — | — | 0.896 |
| 8 | 3d1f89ec-ac0b-40f8-ac89-ed0c2d4967b7 | — | — | 0.896 |
| 9 | 504282dd-4fef-4f70-a709-6a545d00a263 | — | — | 0.891 |
| 10 | TCGA-22-5481-01A-31R-1949-07 | — | cohortMD1 | 0.891 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.710 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.620 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.590 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.570 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.310 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.280 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.260 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.070 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.040 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.020 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.020 | Inavolisib | — uncovered |